Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

Celltrion announced that its Brazilian subsidiary won the Federal Government of Brazil’s bid to supply HERZUMA (trastuzumab-pkrb) for the fifth consecutive year, with around 660,000 vials to be ...

About Ignite Proteomics Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., specializes in advanced RPPA technology for cancer diagnostics. As the only provider of a CLIA-accredited RPPA assay ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Researchers have developed a tool that provides new insights into cause-and-effect relationships between cells and how these ...

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

For patients undergoing treatment for certain types of cancer, artificial intelligence (AI) can use electrocardiographic (ECG ...

Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

In this article, we discuss the global issue of drug shortages. We summarise our research where we developed a framework for ...